Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.38 |
| ▸ | EDNRA | P25101 | 1/20 | 0.37 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.34 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.34 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 5/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23930238 | 1.00 | GBA1 (0.39) | GBA1NUDT1EDNRAFDPSMEN1 | |
| SCHEMBL23930009 | 0.82 | GBA1 (0.41) | GBA1MEN1MAPTKMT2ANPC1 | |
| SCHEMBL30175347 | 0.82 | GBA1 (0.41) | GBA1MEN1MAPTKMT2ANPC1 | |
| SCHEMBL23930192 | 0.82 | GBA1 (0.41) | GBA1MEN1MAPTKMT2ANPC1 | |
| SCHEMBL23930232 | 0.80 | GBA1 (0.67) | GBA1NPC1ALDH1A1MAPK1KDM4E | |
| SCHEMBL23930230 | 0.80 | GBA1 (0.67) | GBA1NPC1ALDH1A1MAPK1KDM4E | |
| SCHEMBL23957717 | 0.78 | GBA1 (0.39) | GBA1MEN1KMT2ANNMTPDE4A | |
| SCHEMBL31217405 | 0.76 | GBA1 (0.53) | GBA1EDNRAFDPSMEN1TP53 | |
| SCHEMBL182965 | 0.75 | — | — | |
| SCHEMBL30057293 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115605477-B | Pyrazolo [1,5-a ] pyridine derivative, preparation method, composition and application thereof | 深圳众格生物科技有限公司 | 2024-07-05 | — | — | CN | disclosed |
| US-20230159523-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | SHENZHEN ZHONGGE BIOLOGICAL TECHNOLOGY CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| EP-4141003-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | Shenzhen Zhongge Biological Technology Co., Ltd. (CN) | 2023-03-01 | — | — | EP | disclosed |
| CN-115605477-A | Pyrazolo [1,5-a ] pyridine derivative and preparation method, composition and application thereof | 深圳众格生物科技有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| WO-2021213476-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | 深圳晶泰科技有限公司 (CN) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159523-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | NCOA4, CCDC47, CCDC6 | GBA1 3054/4885NUDT1 3254/4885EDNRA 4345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.